Canaccord Genuity reiterates Buy rating on 10X Genomics stock at $15

Canaccord Genuity maintains its Buy rating and $15 price target on 10X Genomics (TXG), citing the company's strong Q1 2025 performance that exceeded consensus, its robust 68% gross margin, and a net cash position. The firm believes TXG is well-positioned to capitalize on growth in large-scale single-cell and multiomics applications, including increasing AI integration and a strategic shift towards biopharma revenue, further bolstered by a recent $68 million patent settlement with Bruker. While TXG withdrew its 2025 revenue guidance due to macroeconomic concerns, Canaccord views the company's leading market position and financial health as undervalued, despite near-term uncertainties.

Analysis

Canaccord Genuity has reiterated its Buy rating and $15.00 price target for 10X Genomics (TXG), underpinning a bullish outlook based on the company's leadership in single-cell analysis and multiomics. The firm highlights significant revenue potential from large-scale research projects and the increasing application of AI in analyzing complex biological data. This is supported by TXG's strategic objective to increase its biopharma revenue contribution from 20% to 50%. Financially, the company demonstrates a robust position with a 68% gross profit margin and a balance sheet holding more cash than debt. This strength was underscored by Q1 2025 results that surpassed consensus expectations, driven by strong consumables revenue, even after excluding a one-time patent litigation settlement. However, this positive operational performance is tempered by significant near-term uncertainty, as TXG has withdrawn its full-year 2025 revenue guidance, citing a challenging macroeconomic environment. The company projects Q2 revenue to be flat with Q1, excluding settlement benefits. The recent resolution of all global patent litigation with Bruker, which includes a $68 million payment to TXG, removes a key overhang and provides further balance sheet support, while its sequencer-agnostic model is noted as a mitigator against geopolitical risks in China.

Key Decisions for Investors

• Investors should weigh the company's strong long-term growth drivers, including its market leadership, robust margins, and expansion into biopharma, against the near-term volatility created by the withdrawal of 2025 revenue guidance due to macroeconomic pressures.
• Monitor consumables revenue, particularly from Xenium, as a key indicator of underlying business momentum, and track progress toward the strategic goal of achieving a 50% biopharma revenue mix.
• Consider the recent $68 million patent settlement with Bruker as a de-risking event that resolves a major legal uncertainty and strengthens the company's cash position.
• Pay close attention to future management commentary regarding the macroeconomic landscape, as any reinstatement of guidance or updated outlook will be a critical catalyst for the stock.